| Ytd | -21.32% | |
| 1y | 47.85% |
| Open | 15.31 | Prev Close | 15.14 | Low | 15.20 | High | 16.80 | Mkt Cap | 242.63M |
| Vol | 119.88K | Avg Vol | 138.91K | EPS | -1.68 | P/E | N/A | Forward P/E | -14.83 |
| Beta | 3.32 | Short Ratio | 21.41 | Inst. Own | 8.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 16.41 | 200-d Avg | 21.98 | 1yr Est | 38.00 |
GLSI News
Greenwich LifeSciences, Inc. (NASDAQ: GLSI - Get Free Report)'s stock price fell 2.1% during mid-day
Certain stocks are such poor bets that they are likely to lose ground even in bull markets.
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
STAFFORD, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
STAFFORD, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
HC Wainwright & Co. analyst Yi Chen maintains Greenwich LifeSciences (NASDAQ:GLSI) with a Buy
FLAMINGO-01 Data Safety Monitoring Board (DSMB)The FLAMINGO-01 DSMB met in May 2026 and recommended
STAFFORD, Texas, July 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
STAFFORD, Texas, July 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
Greenwich LifeSciences is a single-asset biotech focused on GLSI-100, an immunotherapy for HER2-posi
All European and US Sites to Treat Patients with Commercially Manufactured GP2The Company previously
STAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
Greenwich LifeSciences (NASDAQ:GLSI) reported quarterly losses of $(0.58) per share which missed the
from the ASCO Annual Meeting 2026.The abstract is shown below and the poster being presented today c
STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) ("Greenwich" or the "Company"), a clinica
STAFFORD, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) ("Gree
STAFFORD, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
STAFFORD, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
STAFFORD, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
STAFFORD, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
STAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) shares are trading higher after the company announced the
BABA: 5% | Alibaba shares are trading higher on Bloomberg report of company moving toward IPO of its
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
HC Wainwright & Co. analyst Yi Chen maintains Greenwich LifeSciences (NASDAQ:GLSI) with a Buy
Greenwich LifeSciences shares are trading higher Monday after the company announced it extended its
Greenwich LifeSciences stock hits a new 52-week high! Discover how Greenwich LifeSciences is streaml
On Monday, 369 companies set new 52-week lows.